RxDoctor Payments Data

Victor Ylagan, MD

Neurology · New Milford, CTNPI 1265464945

Payments from drug & device makers

$19,376in general payments, 2019–2025

Across 950 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • EMD Serono, Inc.$2K
  • SK Life Science, Inc.$1K
  • Biogen$1K
  • Amgen$1K
  • UCB, Inc.$650
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$1921%
  • Food & beverage$19,05798%
  • Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)161$2,129
EMD Serono, Inc.61$1,739
SK Life Science, Inc.68$1,407
Biogen60$1,214
Amgen(2 entities)50$1,179
UCB, Inc.29$650
Neurocrine Biosciences, Inc.31$603
Lilly USA, LLC30$598
Genentech USA, Inc.22$560
Teva Pharmaceuticals USA, Inc.28$558
Novartis33$554
Lundbeck LLC23$445
AstraZeneca22$436
Argenx US, Inc.11$402
Pfizer21$391
Amneal Pharmaceuticals LLC23$391
Sanofi20$367
Johnson & Johnson9$342
Bristol Myers Squibb17$325
TG Therapeutics, Inc.10$318
Sunovion Pharmaceuticals Inc.19$314
Eisai Inc.14$301
E.r. Squibb & Sons, L.L.C.5$298
GE HealthCare11$276
Akcea Therapeutics, Inc.7$271
Otsuka America Pharmaceutical, Inc.10$260
Takeda Pharmaceuticals U.S.A., Inc.16$257
MDD US Operations, LLC10$234
Upsher-smith Laboratories LLC11$198
Acorda Therapeutics, Inc10$192
Neurelis, Inc.8$185
Avanir Pharmaceuticals, Inc.7$166
Biohaven Pharmaceutical Holding Company Ltd.9$152
Boston Scientific1$147
Grifols USA, LLC7$139
Kyowa Kirin, Inc.7$136
Adamas Pharmaceuticals, Inc.7$121
Supernus Pharmaceuticals, Inc.6$118
Adlon Therapeutics L.p.6$111
Jazz Pharmaceuticals Inc.5$89
Arbor Pharmaceuticals, Inc.4$69
Biohaven Pharmaceuticals, Inc.4$61
Avion Pharmaceuticals3$58
Acadia Pharmaceuticals Inc3$58
Bausch Health US, LLC3$57
Shire North American Group Inc3$54
Insightec,inc2$50
Mallinckrodt Enterprises LLC3$48
Scilex Pharmaceuticals Inc.3$42
Collegium Pharmaceutical, Inc.2$41
Promius Pharma LLC2$31
Vertical Pharmaceuticals, LLC2$28
Neuropace, Inc.1$25
Xeris Pharmaceuticals, Inc.1$22
Ironshore Pharmaceuticals Inc.1$22
CSL Behring1$22
Currax Pharmaceuticals LLC1$20
Catalyst Pharmaceuticals, Inc.1$18
Alnylam Pharmaceuticals Inc.1$18
Merz North America, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,376 in reported general payments places this provider in the 70th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$59,852
Medicare patients
193
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate14$119,430
XcopriCenobamate38$48,055
MigergotErgotamine Tartrate/Caffeine15$36,147
GlatopaGlatiramer Acetate11$15,339
Tegretol XrCarbamazepine22$4,753
Levetiracetam85$2,546
Gabapentin107$2,529
Oxcarbazepine20$2,369
Lacosamide18$2,320
Quetiapine Fumarate69$2,067
Primidone94$1,857
AmantadineAmantadine Hcl29$1,793
Carbidopa-Levodopa ErCarbidopa/Levodopa12$1,780
Memantine Hcl44$1,742
Donepezil Hcl172$1,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$603$119,43014 claims
SK Life Science, Inc.Xcopri$1,407$48,05538 claims
AmgenMigergot$1,179$36,14715 claims
Upsher-smith Laboratories LLCTopiramate$198$39743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 280 neurology providers in Connecticut.

Other neurology in New Milford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →